Camlin Fine Sciences shareholders approve FY26 financials, reappoint directors
Camlin Fine Sciences Limited concluded its 33rd AGM on August 11, 2026, with shareholders approving FY26 financials and reappointing directors Harsha Raghavan and Jens Van Nieuwenborgh. Voting participation reached 56.83%, with all resolutions passing by over 99.99% majority. The Statutory Auditor issued an unqualified report, and the Cost Auditor’s remuneration for FY27 was ratified.

*this image is generated using AI for illustrative purposes only.
Camlin Fine Sciences Limited shareholders approved the company’s audited financial statements for the fiscal year ended March 31, 2026, and reappointed two non-executive directors at its 33rd Annual General Meeting (AGM) held on August 11, 2026. The meeting, chaired by Chairman and Managing Director Ashish Dandekar, was conducted through Video Conferencing (VC) / Other Audio Visual Means (OAVM) in compliance with Ministry of Corporate Affairs and Securities and Exchange Board of India (SEBI) circulars. All four resolutions placed before the shareholders were passed with requisite majority, reflecting strong support from both promoter and public stakeholders.
The AGM transacted ordinary business including the adoption of standalone and consolidated financial statements for FY26, alongside the re-appointment of Harsha Raghavan and Jens Van Nieuwenborgh as Non-Executive Non-Independent Directors, who retired by rotation. Under special business, shareholders ratified the remuneration of the Cost Auditor for the financial year ending March 31, 2027. The proceedings were scrutinized by Jayant Ranade of JHR & Associates, appointed as Scrutinizer pursuant to Section 108 of the Companies Act, 2013 and Regulation 44 of the SEBI Listing Regulations.
Voting participation was robust, with 56.83% of outstanding shares polled across all resolutions. Promoter and Promoter Group shareholders, holding 92,264,053 shares, voted in favor of all resolutions with 100% support. Public Institutional shareholders also demonstrated high engagement, polling over 84% of their holdings. Remote e-voting was open from August 8 to August 10, 2026, while additional voting occurred during the live meeting session.
Voting Results Summary
| Resolution | Total Votes Polled | Votes In Favor | % In Favor | Votes Against | % Against |
|---|---|---|---|---|---|
| Adoption of Financial Statements (FY26) | 109,167,921 | 109,167,821 | 99.9999% | 100 | 0.0001% |
| Re-appointment of Harsha Raghavan | 109,219,228 | 109,217,553 | 99.9985% | 1,675 | 0.0015% |
| Re-appointment of Jens Van Nieuwenborgh | 109,219,128 | 109,217,453 | 99.9985% | 1,675 | 0.0015% |
| Ratification of Cost Auditor Remuneration | 109,219,276 | 109,219,126 | 99.9999% | 150 | 0.0001% |
The Statutory Auditor’s report contained no qualifications or adverse remarks, as noted by the Chairman during the proceedings. The Scrutinizer’s consolidated report confirmed that no invalid votes were identified during the scrutiny process. A limited number of abstentions were recorded for specific resolutions but were classified separately as votes not cast.
What the Numbers Show
The near-unanimous approval of all resolutions underscores stable shareholder confidence in Camlin Fine Sciences’ governance structure. The promoter group’s complete alignment with all proposals, combined with high institutional participation, suggests minimal dissent regarding the company’s strategic direction and financial reporting for FY26. The negligible percentage of votes against any resolution indicates broad consensus among equity holders.
Historical Stock Returns for Camlin Fine Sciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.91% | -2.31% | -2.36% | -25.01% | -44.52% | -26.31% |
How might the reappointment of Harsha Raghavan and Jens Van Nieuwenborgh influence Camlin Fine Sciences' strategic focus on specialty chemicals in the upcoming fiscal year?
Given the near-unanimous shareholder approval, what specific operational or financial targets has management set for FY27 to maintain this high level of investor confidence?
Could the robust institutional participation (84% polling) indicate a shift in sentiment regarding the company's valuation or growth prospects compared to previous years?

































